Related Experiment Video
Updated: Dec 27, 2025

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
Microcin H47: A Class IIb Microcin with Potent Activity Against Multidrug Resistant Enterobacteriaceae
Jacob D Palmer1, Benedikt M Mortzfeld1,2,3, Emma Piattelli2
1Department of Bioengineering, University of Massachusetts Dartmouth, 285 Old Westport Road, N. Dartmouth, Massachusetts 02747-2300, United States.
Abstract:
Microcin H47 (MccH47) is an antimicrobial peptide produced by some strains of Escherichia coli that has demonstrated inhibitory activity against enteric pathogens in vivo and has been heterologously overexpressed in proof-of-concept engineered probiotic applications. While most studies clearly demonstrate inhibitory activity against E. coli isolates, there are conflicting results on the qualitative capacity for MccH47 to inhibit strains of Salmonella. Here, we rectify these inconsistencies via the overexpression and purification of a form of MccH47, termed MccH47-monoglycosylated enterobactin (MccH47-MGE). We then use purified MccH47 to estimate minimum inhibitory concentrations (MICs) against a number of medically relevant Enterobacteriaceae, including Salmonella and numerous multidrug resistant (MDR) strains. While previous reports suggested that the spectrum of activity for MccH47 is quite narrow and restricted to activity against E. coli, our data demonstrate that MccH47 has broad and potent activity within the Enterobacteriaceae family, suggesting it as a candidate for further development toward treating MDR enteric infections.
Insights
Microcin H47 (MccH47) effectively inhibits a broad range of enteric bacteria, including multidrug-resistant strains. This antimicrobial peptide shows promise for treating challenging enteric infections.
Area of Science:
- Microbiology
- Antimicrobial Peptides
Background:
- Microcin H47 (MccH47), an antimicrobial peptide from *Escherichia coli*, has shown potential in engineered probiotics.
- Previous studies reported conflicting results regarding MccH47's inhibitory activity against *Salmonella* species.
Discussion:
- This study clarifies MccH47's activity spectrum by purifying and testing MccH47-monoglycosylated enterobactin (MccH47-MGE).
- Minimum inhibitory concentrations (MICs) were determined for medically relevant *Enterobacteriaceae*, including *Salmonella* and multidrug-resistant (MDR) strains.
Key Insights:
- Contrary to prior assumptions, MccH47 exhibits broad and potent activity against the *Enterobacteriaceae* family.
- The peptide's efficacy extends to numerous multidrug-resistant strains, challenging previous narrow-spectrum assessments.
Outlook:
- MccH47 demonstrates significant potential as a therapeutic candidate for combating MDR enteric infections.
- Further development of MccH47 is warranted based on its broad-spectrum antimicrobial properties.
More Related Videos
Related Concept Videos
Development of Antibiotic Resistance
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Antimicrobial Effectiveness

